Brought to you by 
Valeant buys Xcel for $280mm
Feb 2005
Executive Summary
To expand its North American neurology business, Valeant Pharmaceuticals International (neurology, dermatology, and infectious disease therapeutics) has agreed to acquire privately held Xcel Pharmaceuticals, a biotech company specializing in CNS drugs, for $280mm in cash, which includes the assumption of $44mm in debt.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Full Acquisition
- Payment Includes Stock
- Includes Contract
- Acquisition of Private Biotech
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant buys Xcel for $280mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice